These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. Parmar SR; Bhatt V; Yang J; Zhang Q; Schuster M J Oncol Pharm Pract; 2014 Jun; 20(3):172-82. PubMed ID: 23804627 [TBL] [Abstract][Full Text] [Related]
65. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France. Watt M; Dinh A; Le Monnier A; Tilleul P J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963 [TBL] [Abstract][Full Text] [Related]
66. Risk factors and clinical outcomes of candidaemia in patients treated for Clostridium difficile infection. Russo A; Falcone M; Fantoni M; Murri R; Masucci L; Carfagna P; Ghezzi MC; Posteraro B; Sanguinetti M; Venditti M Clin Microbiol Infect; 2015 May; 21(5):493.e1-4. PubMed ID: 25698658 [TBL] [Abstract][Full Text] [Related]
67. Hypersensitivity Reaction Following Administration of Low-Dose Oral Vancomycin for the Treatment of Clostridium difficile in a Patient With Normal Renal Function. Baumgartner LJ; Brown L; Geier C J Pharm Pract; 2017 Dec; 30(6):650-652. PubMed ID: 27630210 [TBL] [Abstract][Full Text] [Related]
68. Clostridium difficile infection in children: epidemiology and risk of recurrence in a low-prevalence country. Lo Vecchio A; Lancella L; Tagliabue C; De Giacomo C; Garazzino S; Mainetti M; Cursi L; Borali E; De Vita MV; Boccuzzi E; Castellazzi L; Esposito S; Guarino A Eur J Clin Microbiol Infect Dis; 2017 Jan; 36(1):177-185. PubMed ID: 27696233 [TBL] [Abstract][Full Text] [Related]
69. Evaluation of a Clostridium difficile infection management policy with clinical pharmacy and medical microbiology involvement at a major Canadian teaching hospital. Yeung SS; Yeung JK; Lau TT; Forrester LA; Steiner TS; Bowie WR; Bryce EA J Clin Pharm Ther; 2015 Dec; 40(6):655-60. PubMed ID: 26547905 [TBL] [Abstract][Full Text] [Related]
70. Oral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent Chang LL; Allegretti J; Skinner AM; Dubberke ER N Engl J Med; 2023 Feb; 388(7):654-656. PubMed ID: 36791167 [No Abstract] [Full Text] [Related]
71. Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection. Rafiullah F; Kanwal S; Majeed UM; Korsten MA; Cheema FH; Luthra M; Sohail MR BMJ Case Rep; 2011 Nov; 2011():. PubMed ID: 22674696 [TBL] [Abstract][Full Text] [Related]
73. Clostridium difficile infection, Colorado and the northwestern United States, 2007. Kuntz JL; Johnson ES; Raebel MA; Petrik AF; Yang X; Thorp ML; Spindel SJ; Neil N; Smith DH Emerg Infect Dis; 2012 Jun; 18(6):960-2. PubMed ID: 22608207 [TBL] [Abstract][Full Text] [Related]
74. Oral Vancomycin for Secondary Prophylaxis of Clostridium difficile Infection. Brown CC; Manis MM; Bohm NM; Curry SR Ann Pharmacother; 2019 Apr; 53(4):396-401. PubMed ID: 30450942 [TBL] [Abstract][Full Text] [Related]
75. Letter: faecal microbiota transplantation in combination with fidaxomicin to treat severe complicated recurrent Clostridium difficile infection. Pecere S; Sabatelli M; Fantoni M; Ianiro G; Gasbarrini A; Cammarota G Aliment Pharmacol Ther; 2015 Oct; 42(8):1030. PubMed ID: 26374258 [No Abstract] [Full Text] [Related]
76. Treatment of Clostridium difficile-associated disease with teicoplanin. de Lalla F; Privitera G; Rinaldi E; Ortisi G; Santoro D; Rizzardini G Antimicrob Agents Chemother; 1989 Jul; 33(7):1125-7. PubMed ID: 2528941 [TBL] [Abstract][Full Text] [Related]
77. Letter: faecal microbiota transplantation in combination with fidaxomicin to treat severe complicated recurrent Clostridium difficile infection--authors' reply. Fischer M; Rex DK; Sipe BW Aliment Pharmacol Ther; 2015 Oct; 42(8):1031. PubMed ID: 26374259 [No Abstract] [Full Text] [Related]
78. Does Prophylaxis Prevent Recurrent Berger RE NEJM Evid; 2022 Apr; 1(4):EVIDtt2200026. PubMed ID: 38319213 [TBL] [Abstract][Full Text] [Related]
79. A Propensity-Matched Analysis Between Standard Versus Tapered Oral Vancomycin Courses for the Management of Recurrent Gentry CA; Giancola SE; Thind S; Kurdgelashvili G; Skrepnek GH; Williams RJ Open Forum Infect Dis; 2017; 4(4):ofx235. PubMed ID: 29255732 [TBL] [Abstract][Full Text] [Related]
80. Management of Recurrent Clostridioides Infection: A Difficile Problem in Inflammatory Bowel Disease Patients. Lam AY; Gutin LS; Nguyen Y; Velayos FS Dig Dis Sci; 2020 Nov; 65(11):3111-3115. PubMed ID: 32749638 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]